المؤلفون: Schiller G; Department of Medicine, UCLA School of Medicine, Los Angeles, California, USA., Emmanoulides C, Iastrebner MC, Lee M, Naeim F

المصدر: Leukemia & lymphoma [Leuk Lymphoma] 1996 Feb; Vol. 20 (5-6), pp. 427-34.

نوع المنشور: Clinical Trial; Journal Article

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print Cited Medium: Print ISSN: 1042-8194 (Print) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE

مواضيع طبية MeSH: Antimetabolites, Antineoplastic/*therapeutic use , Cytarabine/*therapeutic use , Granulocyte Colony-Stimulating Factor/*therapeutic use , Immunologic Factors/*therapeutic use , Leukemia, Myeloid/*therapy, Acute Disease ; Adolescent ; Adult ; Aged ; Antimetabolites, Antineoplastic/administration & dosage ; Antimetabolites, Antineoplastic/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Combined Modality Therapy ; Cytarabine/administration & dosage ; Cytarabine/adverse effects ; Disease-Free Survival ; Female ; Filgrastim ; Gastrointestinal Diseases/chemically induced ; Granulocyte Colony-Stimulating Factor/administration & dosage ; Granulocyte Colony-Stimulating Factor/adverse effects ; Humans ; Immunologic Factors/administration & dosage ; Immunologic Factors/adverse effects ; Leukemia, Myeloid/drug therapy ; Leukemia, Myeloid/mortality ; Male ; Middle Aged ; Recombinant Proteins ; Remission Induction ; Salvage Therapy ; Survival Rate ; Treatment Outcome